Neural metabolite changes in corpus striatum after rat multipotent mesenchymal stem cells transplanted in hemiparkinsonian rats by magnetic resonance spectroscopy

International Journal of Neuroscience

Volumn 123, Issue 12, 2013, Pages 883-891

  Fu, Wenyu ^a   Zheng, Zhijuan ^a,b   Zhuang, Wenxin ^a   Chen, Dandan ^a   Wang, Xiaocui ^a   Sun, Xihe ^a   Wang, Xin ^c  

^a WEIFANG MEDICAL UNIVERSITY   (China)

^b SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

MSCs; Neuroprotection; Parkinson's disease; Striatal metabolite

Indexed keywords

BROXURIDINE; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE; ASPARTIC ACID; CHOLINE; CREATINE; MICROTUBULE ASSOCIATED PROTEIN; N-ACETYLASPARTATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CORPUS STRIATUM; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MESENCHYMAL STEM CELL; METABOLITE; MULTIPOTENT MESENCHYMAL STEM CELL TRANSPLANTATION; NERVE CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSONISM; RAT; ROTAROD TEST; STEM CELL TRANSPLANTATION; SUBSTANTIA NIGRA; THERAPY EFFECT; ANALOGS AND DERIVATIVES; ANIMAL; CELL SURVIVAL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; FEMALE; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLISM; PARKINSONIAN DISORDERS; PATHOLOGY; SPRAGUE DAWLEY RAT; TIME; TOXICITY;

ANIMALS; ASPARTIC ACID; CELL DIFFERENTIATION; CELL SURVIVAL; CHOLINE; CORPUS STRIATUM; CREATINE; DISEASE MODELS, ANIMAL; FEMALE; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MICROTUBULE-ASSOCIATED PROTEINS; NEURONS; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 84887935315     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2013.814132     Document Type: Article

References (33)

1. Schulz JB, Falkenburger BH. Neuronal pathology in Parkinson's disease. Cell Tissue Res 2004;318:135-47.
2. Politis M, Lindvall O. Clinical application of stem cell therapy in Parkinson's disease. BMC Med 2012;10:1.
3. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997;276:71-4.
4. Kitada M, Dezawa M. Parkinson's disease and mesenchymal stem cells: potential for cell-based therapy. Parkinsons Dis 2012;2012:873706.
5. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-7.
6. Woodbury D, Schwarz EJ, Prockop DJ, et al. Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res 2000;61:364-70.
7. Wang Y, Yang J, Li H, et al. Hypoxia promotes dopaminergic differentiation of mesenchymal stem cells and shows benefits for transplantation in a rat model of Parkinson's disease. PLoS One 2013;8:e54296.
8. Hayashi T,Wakao S, Kitada M, et al. Autologous mesenchymal stem cell-derived dopaminergic neurons function in Parkinsonian macaques. J Clin Invest 2013;123:272-84.
9. Krampera M, Pasini A, Pizzolo G, et al. Regenerative and immunomodulatory potential of mesenchymal stem cells. Curr Opin Pharmacol 2006;6:435-41.
10. Choumerianou DM, Dimitriou H, Perdikogianni C, et al. Study of oncogenic transformation in ex vivo expanded mesenchymal cells, from paediatric bone marrow. Cell Prolif 2008;41: 909-22.
11. Liu J, Song L, Jiang C, et al. Electrophysiological properties and synaptic function of mesenchymal stem cells during neurogenic differentiation-a mini-review. Int J Artif Organs 2012;35:323-37.
12. Park S, Kim E, Koh SE, et al. Dopaminergic differentiation of neural progenitors derived from placental mesenchymal stem cells in the brains of Parkinson's disease model rats and alleviation of asymmetric rotational behavior. Brain Res 2012;1466:158-66.
13. Hellmann MA, Panet H, Barhum Y, et al. Increased survival and migration of engrafted mesenchymal bone marrow stem cells in 6-hydroxydopamine-lesioned rodents. Neurosci Lett 2006;395:124-8.
14. Deng J, Petersen BE, Steindler DA, et al. Mesenchymal stem cells spontaneously express neural proteins in culture and are neurogenic after transplantation. Stem Cells 2006;24: 1054-64.
15. Blandini F, Cova L, Armentero MT, et al. Transplantation of undifferentiated human mesenchymal stem cells protects against 6-hydroxydopamine neurotoxicity in the rat. Cell Transplant 2010;19:203-17.
16. Urenjak J, Williams SR, Gadian DG, et al. Specific expression of N-acetylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro. J Neurochem 1992;59:55-61.
17. Martin WR. MR spectroscopy in neurodegenerative disease. Mol Imaging Biol 2007;9:196-203.
18. Choi JK, Dedeoglu A, Jenkins BG. Application of MRS to mouse models of neurodegenerative illness. NMR Biomed 2007;20:216-37.
19. The Ministry of Science and Technology of the People's Republic of China. Guidance suggestions for the care and use of laboratory animals. 2006-09-30 20. Kuznetsov SA, Friedenstein AJ, Robey PG. Factors required for bone marrow stromal fibroblast colony formation in vitro. Br J Haematol 1997;97:561-70.
20. Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol 2000;28:875-84.
21. Hussain I, Magd SA, Eremin O, et al. New approach to isolate mesenchymal stem cell (MSC) from human umbilical cord blood. Cell Biol Int 2012;36:595-600.
22. Brundin P, Barker RA, Parmar M. Neural grafting in Parkinson's disease: problems and possibilities. Prog Brain Res 2010;184:265-94.
23. Chao YX, He BP, Tay SS. Mesenchymal stem cell transplantation attenuates blood brain barrier damage and neuroinflammation and protects dopaminergic neurons against MPTP toxicity in the SN in a model of Parkinson's disease. J Neuroimmunol 2009;216:39-50.
24. Nagatsu T,MogiM, Ichinose H, et al. Cytokines in Parkinson's disease. J Neural Transm Suppl 2000;(58):143-51.
25. Venkataramana NK, Pal R, Rao SA, et al. Bilateral transplantation of allogenic adult human bone marrow-derived mesenchymal stem cells into the subventricular zone of Parkinson's disease: a pilot clinical study. Stem Cells Int 2012;2012:931902.
26. Urenjak J,Williams SR, Gadian DG, et al. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 1993;13:981-9.
27. Serles W, Li LM, Antel SB, et al. Time course of postoperative recovery of N-acetyl-aspartate in temporal lobe epilepsy. Epilepsia 2001;42:190-7.
28. Signoretti S, Marmarou A, Fatouros P, et al. Application of chemical shift imaging formeasurement of NAA in head injured patients. Acta Neurochir Suppl 2002;81:373-5.
29. Clarke CE, Lowry M. Systematic review of proton magnetic resonance spectroscopy of the striatum in Parkinsonian syndromes. Eur J Neurol 2001;8:573-7.
30. Choi IY, Lee SP, Guilfoyle DN, et al. In vivo NMR studies of neurodegenerative diseases in transgenic and rodent models. Neurochem Res 2003;28:987-1001.
31. Ross BD,Hoang TQ, Bluml S, et al. In vivo magnetic resonance spectroscopy of human fetal neural transplants. NMR Biomed 1999;12:221-36.
32. Podell M, Hadjiconstantinou M, Smith MA, et al. Protonmagnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of Parkinsonism. Exp Neurol 2003;179:159-66.
33. van Vlieta SA, Blezer EL, JongsmaMJ, et al. Exploring the neuroprotective effects of modafinil in a marmoset Parkinsonmodel with immunohistochemistry, magnetic resonance imaging and spectroscopy. Brain Res 2008;1189:219-28.